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and Fuks, 2003; Paris et al., 2001), sug-
gesting that this represents a generic
response mechanism for mammalian tis-
sue damage by large single-dose irradia-
tion. The possibility that a similar
crosstalk between microvasculature and
tumor clonogens occurs during fraction-
ated radiotherapy when the HIF-1-medi-
ated endothelial protection is removed,
such as reported by Moeller et al., repre-
sents a testable hypothesis.
In principle, the studies of Moeller et
al. support the notion that fractionated
radiotherapy, like single-dose radiation,
engages a vascular component of the
tumor response. In the case of fractionat-
ed radiotherapy, however, this response
is largely attenuated by adaptive signals
generated by HIF-1 activation. Hence,
Moeller et al. suggest that HIF-1 may
represent a valid target for radiosensiti-
zation via derepression of endothelial
cell death. However, they caution that
HIF-1 inactivation, if it is to be therapeuti-
cally efficacious, should be scheduled to
optimize tumor cell radiosensitization. In
contrast, the endothelial death signal
produced by large-dose exposure
(>8–10 Gy) may precede or be of suffi-
cient magnitude to overcome HIF-1 anti-
death protection. These provocative
studies should open up new avenues for
basic research into mechanisms of
endothelial cell damage and the role of
the microvascular response in therapy,
potentially providing new pharmacologic
targets for improving radiation and other
anticancer treatments.
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P R E V I E W S
Hereditary tumor syndromes have
given numerous insights into cancer biol-
ogy. Often it is straightforward to see a
link between the genetic defect and
tumor predisposition. This is the case if
the gene product impinges on pathways
involved in cell proliferation or cell death.
In other examples, maintenance of the
genome is compromised, so that the like-
lihood of developing mutations that lead
to an increase in proliferation or death is
increased. But the link between the
genetic defect and tumor predisposition
is not always clear. Arguably, these
cases are most likely to lead to truly
novel insights into tumor development. A
paper from Bill Kaelin’s group in this
issue of Cancer Cell suggests that
apparently unlinked genes implicated in
paraganglioma act in a single common
pathway (Lee et al., 2005). The authors
provide evidence that all the genetic
defects act by decreasing the likelihood
of apoptosis of neural crest cells at the
time during development when levels of
nerve growth factor (NGF) become limit-
ing. The study gives particular insight
into the interesting issue of how muta-
tions affecting succinate dehydrogenase
components could be tumorigenic.
Paragangliomas are tumors of the
autonomic nervous system. Non-
chromaffin paragangliomas are rare, are
described as “chemodectomas,” and are
located in the head and neck. Chromaffin
paragangliomas are much commoner,
have endocrine activity, and are referred
to as “pheochromocytomas.” These are
usually located in the adrenal medulla
but sometimes occur in the pre- and par-
avertebral thoracoabdominal regions.
Familial paraganglioma syndromes can
A common pathway for genetic events leading to
pheochromocytoma
Mutations in VHL, RET, NF1, SDHB, SDHC, and SDHD can give rise to pheochromocytoma/paraganglioma.These different
genetic lesions may all act by decreasing the activity of a 2-oxoglutarate-dependent oxygenase, SM-20/EglN3/PHD3,
resulting in reduced apoptosis of neural crest cells during development.
Figure 1. As NGF levels become limiting dur-
ing development, mutations affecting NF1,
RET, VHL, and SDH subunits all decrease
apoptosis mediated by SM-20/EglN3/PHD3.
Adapted from Lee et al. (2005) to show inter-
actions with HIF.
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manifest as nonchromaffin head and
neck tumors only, adrenal and/or extra-
adrenal pheochromocytomas only, or a
combination of the two types of tumors.
When pheochromocytomas occur in
families, they may be associated with
other abnormalities as part of three
hereditary multitumor syndromes: von
Hippel-Lindau (VHL) disease, type I neu-
rofibromatosis, and type II multiple
endocrine neoplasia (Maher and Eng,
2002). These are, respectively, caused
by inactivating mutations in VHL or NF1,
or activating mutations in RET. Other
families have paraganglioma alone, with
mutations in succinate dehydrogenase
subunits B, C, or D, or mutations in VHL
or RET. Importantly, about 25% of 
individuals with apparently sporadic
pheochromocytoma have germline
mutations in one of the genes involved in
familial paraganglioma syndromes
(Neumann et al., 2002). An intriguing
puzzle has been how these apparently
very different genetic lesions all lead to a
similar phenotype.
The Kaelin group has made a num-
ber of seminal contributions to under-
standing the function of the VHL gene,
beginning with their demonstration that
it suppressed the growth of clear cell
renal cell carcinoma (CCRCC) cells in
xenografts (Iliopoulos et al., 1995). They
and others went on to show that VHL-
defective CCRCC cells exhibit constitu-
tively high expression of certain gene
products normally upregulated in low
oxygen. Our own studies established
that this is because VHL is necessary
for the oxygen-dependent inactivation of
hypoxia-inducible factor (HIF) (Maxwell
et al., 1999). HIF activation is necessary
and sufficient for many of the manifesta-
tions of VHL loss of function, including
growth of CCRCC cells as xenografts
(Kondo et al., 2003). However, there are
cogent lines of evidence that VHL has
other functions besides its role in regu-
lating HIF. In C. elegans, there are a sub-
set of genes that are dysregulated in
vhl-1 mutants that are not normalized in
vhl-1/hif-1 double mutants (Bishop et al.,
2004). In humans, certain mutations in
VHL have been associated with familial
pheochromocytoma alone (type IIC VHL
disease), and these mutations do not
appear to alter the ability to regulate HIF.
This strongly suggested that VHL-relat-
ed pheochromocytoma might not be
related to HIF activation and that mis-
sense mutations in VHL associated with
type IIC disease would offer a powerful
tool to identify HIF-independent actions
of VHL.
The study in this issue of Cancer Cell
shows that VHL suppresses JunB and
that all mutations tested—including
those associated with type IIC VHL dis-
ease—abrogate its ability to do so (Lee
et al., 2005). JunB acts as an antagonist
of c-Jun, blunting c-Jun-mediated apop-
tosis as NGF levels become limiting.
There is previous evidence to suggest
that RET (the receptor for glial-derived
neurotrophic factor [GDNF]) and NF1
could act through this pathway by modu-
lating the action of the NGF receptor
TrkA. The study goes on to examine the
downstream effector pathway, using a
variety of approaches to investigate the
role of a protein initially identified as SM-
20 in rat smooth muscle cells and subse-
quently implicated in apoptosis in neural
crest-derived cells. SM-20 is now known
to be a 2-oxoglutarate-dependent prolyl
hydroxylase (see below). The current
study provides clear evidence that this
enzyme is necessary and sufficient for
increased apoptosis on NGF withdrawal,
and that the action is abolished by a
mutation that will abrogate oxygenase
activity. The 2-oxoglutarate-dependent
oxygenases produce succinate as an
end product, providing a tantalizing
potential link to succinate dehydroge-
nase. This is because decreased SDH
activity has been shown to result in accu-
mulation of succinate, which inhibits SM-
20 activity. Thus, all the genetic lesions
associated with pheochromocytoma are
proposed to act on a single common
pathway that is responsible for culling
precursor cells during development
(Figure 1).
One satisfying aspect is that these
findings provide an explanation as to why
the mutations in tumor suppressors that
are found in familial paraganglioma syn-
dromes are rare in sporadic pheochromo-
cytoma, except as occult germline
mutations. This is because the pathway is
no longer critical once development is
completed. From a therapeutic perspec-
tive, it suggests that premalignant lesions
will be present in at-risk individuals and
could be ablated before they develop into
pheochromocytoma. A second clinically
relevant aspect is that it would explain
why mutations are not found in more 
than one of these genes in individual
cases/kindreds, since they would not
have additive effects. The study also con-
firms previous findings that VHL regulates
atypical protein kinase C (aPKC) activity
and shows that this effect is independent
of HIF activation. It seems likely that this
involves selective ubiquitylation of phos-
phorylated aPKC, and it will be interesting
to understand the molecular interaction
underlying this.
An important issue is whether HIF—
which could almost be regarded as
VHL’s alter ego—has any role in the
pheochromocytoma pathway. Although
HIF doesn’t seem to be involved, poten-
tial links keep cropping up (Figure 1).
First, part of the effect of VHL status on
JunB is mediated by HIF. Second, SM-
20 is itself involved in the HIF/VHL path-
way. Some years after SM-20 was first
identified, it was isolated as one of a
family of three iron- and 2-oxoglutarate-
dependent oxygenases that hydroxylate
HIF α subunits at conserved prolyl
residues—termed PHD, HIF-PH, or
EglN enzymes (Schofield and Ratcliffe,
2004). This hydroxylation provides the
recognition signal that enables HIF α
subunits to be captured by VHL. Indeed,
it was previously reported that
decreased activity of SDH is sufficient to
activate HIF (Selak et al., 2005).
Nevertheless, under standard condi-
tions PHD2/EglN1 is the predominant
HIF hydroxylase, and RNAi knockdown
of SM-20/PHD3/EglN3 alone does not
generally lead to HIF activation (Berra et
al., 2003). Third, it is intriguing that SM-
20/EglN3/PHD3 is a transcriptional tar-
get of HIF, with expression increasing in
low oxygen tension by as much as two to
three orders of magnitude. VHL inactiva-
tion results in HIF activation in all cell
types examined to date, so it would have
been predicted that VHL loss of function
would result in increased expression of
SM-20/EglN3/PHD3. Importantly, Lee et
al. find that amongst VHL mutations that
ablate its ability to regulate HIF, there
are differential effects on the expression
of SM-20/EglN3/PHD3 (Lee et al.,
2005). Thus, the mutations tested that
are associated with a high risk of
pheochromocytoma suppressed SM-
20/EglN3/PHD3, even if they failed to
suppress HIF. Overall, the potential
interactions of the proposed pathway
with HIF suggest that it would be 
premature to exclude a role in pheo-
chromocytoma.
Understanding how mutations affect-
ing succinate dehydrogenase are tumori-
genic is likely to have implications
beyond pheochromocytoma. Mutations
in another tricarboxylic acid cycle
enzyme, fumarate hydratase (FH), were
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recently found to underlie a different
hereditary tumor syndrome, familial
leiomyomatosis and renal cell cancer
(Eng et al., 2003). Isaacs et al. report in
this issue that decreased activity of FH
inhibits HIF hydroxylase activity (Isaacs
et al., 2005). So there is an emerging pic-
ture that TCA cycle defects can impact
key enzyme reactions by altering the
concentration of fumarate and succinate.
This is an alternative to the hypothesis
that loss of function of FH or SDH sub-
units acts through mitochondrial dys-
function and increased generation of
reactive oxygen species (Eng et al.,
2003). So far, studies have focused on
HIF hydroxylases, but these form only
one branch of an extensive family of 
2-oxoglutarate-dependent oxygenases
whose activity might be modulated.
In any event, a spotlight is now on
EglN3/PHD3, and it will be interesting to
determine if mutations in this gene
occur in pheochromocytoma, or in other
tumors. An important challenge is iden-
tifying the link between the enzyme and
apoptosis, which presumably involves
hydroxylation of a protein other than
HIF.
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Metastasis, the spread of cancer
from the primary site of tumor growth to
other organs, is the leading cause of can-
cer-related morbidity and mortality. It is a
sequential process, contingent on tumor
cell acquisition of the following capabili-
ties: invasion, survival and arrest in the
bloodstream, extravasation, and colo-
nization at a distant site. Layered onto
these general requirements of metasta-
sis, tumor cells may acquire the capacity
to preferentially colonize distinct organs.
Over a century ago, Paget compared
metastatic tumor cells to widely dissemi-
nated seeds, which will grow only on fer-
tile soils (Paget, 1889). This vision
propelled the hypothesis that tumor cell-
host interactions serve as the prime con-
tributor to organ-specific metastasis. An
understanding of metastatic colonization,
both general and organ specific, may be
key to the development of antimetastatic
therapies; the final step of colonization
has not been completed in the majority of
cancer patients at the time of diagnosis
and surgery and is therefore amenable to
therapeutic targeting (Steeg, 2003).
Tissue tropism or organ-specific
homing of cancer cells depends on both
the histology and the stage of cancer.
Ocular melanomas stand as a stunning
example of this tropism, metastasizing
preferentially to the liver. Other cancers,
such as breast, metastasize to multiple
sites, most commonly lung and bone tis-
sue and with less frequency the liver and
the adrenal glands. Several factors are
thought to influence the site of cancer
metastasis, and these include (1) the
pattern and direction of blood flow from
the primary tumor, (2) mechanical trap-
ping of tumor cells at a secondary site by
small capillary beds, (3) tumor cell adhe-
sion at a secondary site by the expres-
sion of appropriate cell surface proteins,
Metastasis gets site specific
Organ-specific homing and colonization of cancer cells are important and interesting features of metastasis. Molecular
programs that contribute to this tropism may be elucidated through gene expression profiling with DNA microarrays. Using
experimentally derived breast cancer cells that home specifically to bone or to lung, several investigators have concluded
that distinct alterations in gene expression underlie metastasis to these sites. Minn et al. (2005) report a set of genes
involved in lung-specific metastasis of breast cancer; the authors have determined the functional contribution of several
genes to the metastatic cascade, as well as the relevance of these genes to human disease.
